These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Role of androgens in surgical menopause. Gelfand MM. Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 2):S325-7. PubMed ID: 10076173 [Abstract] [Full Text] [Related]
3. Practical clinical considerations in the use of estrogen/androgen therapy. A case-based forum. Metzger DA, Chosak R, Leventhal J, Young RL. J Reprod Med; 1998 Aug; 43(8 Suppl):753-62. PubMed ID: 9750205 [No Abstract] [Full Text] [Related]
4. Practice patterns with hormone therapy after surgical menopause. Chubaty A, Shandro MT, Schuurmans N, Yuksel N. Maturitas; 2011 May; 69(1):69-73. PubMed ID: 21396791 [Abstract] [Full Text] [Related]
6. Androgen cotherapy in menopause: evolving benefits and challenges. Bachmann GA. Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 2):S308-11. PubMed ID: 10076169 [Abstract] [Full Text] [Related]
7. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Sherwin BB. Int J Fertil Womens Med; 1998 Mar; 43(2):98-103. PubMed ID: 9609209 [Abstract] [Full Text] [Related]
8. Efficacy and safety of estrogen/androgen therapy. Menopausal symptoms, bone, and cardiovascular parameters. Barrett-Connor E. J Reprod Med; 1998 Aug; 43(8 Suppl):746-52. PubMed ID: 9750204 [No Abstract] [Full Text] [Related]
9. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Menopause; 1999 Aug; 6(2):138-46. PubMed ID: 10374221 [Abstract] [Full Text] [Related]
10. Patient profile 3: decreased libido and bone mineral density in a naturally menopausal woman. Burnett RG. Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 2):S334-6. PubMed ID: 10076176 [No Abstract] [Full Text] [Related]
11. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Int J Fertil Womens Med; 2007 Mar; 52(2-3):93-6. PubMed ID: 18320867 [Abstract] [Full Text] [Related]
12. Hormones and quality of life after surgical menopause. Utian WH. J Womens Health (Larchmt); 2006 Oct; 15(8):975-6. PubMed ID: 17087621 [No Abstract] [Full Text] [Related]
13. Type of menopause, patterns of hormone therapy use, and hot flashes. Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA. Fertil Steril; 2006 May; 85(5):1432-40. PubMed ID: 16566933 [Abstract] [Full Text] [Related]
14. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568 [Abstract] [Full Text] [Related]